RNS4 Dec 2018 09:11
Scope expanded with top 10 biopharma company
Tue, 4th Dec 2018 07:00
RNS Number : 3018J
IXICO plc
04 December 2018
4 December 2018
IXICO plc
("IXICO" or the "Company")
IXICO signs expanded scope to current contract with top 10 biopharmaceutical company
Increasing contract value by $2.4m over the remaining term
IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, today announces that it has signed an expanded scope to a current contract with a top 10 biopharmaceutical company. Additional services will be provided, increasing the value of the contract by $2.4m over the remaining 6-year term of the agreement. As a result, the contract value has increased from $2.7m to $5.1m.
The expanded scope will see IXICO providing additional imaging services, to a significantly higher number of patients, and an increased number of participating international study sites.
Giulio Cerroni, Chief Executive of IXICO, said: "I am delighted that our client has decided to expand our involvement in this important study. We value the strength of our relationships with biopharmaceutical companies and our ability to provide them with important insights that support their efforts to bring new therapies to market. This latest increase in scope demonstrates IXICO's ability to efficiently scale operations and adapt to changing requirements as global clinical studies progress."
For further information please contact:
IXICO plc
Giulio Cerroni, Chief Executive Officer
Susan Lowther, Chief Financial Officer
Tel: +44 20 3763 7499
Shore Capital (Nomad and Broker)
Edward Mansfield/Anita Ghanekar/Daniel Bush
Tel: +44 20 7408 4090
FTI Consulting Limited (Investor Relations)
Simon Conway/Mo Noonan
Tel: +44 20 3727 1000
Sign In
Follow the stocks
